Advisors



Simon Douglas PhD - Commercial advisor

Simon has over 25 years’ experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was sold to Agilent Technologies Inc and is currently a director of the antibody-based therapeutics Company Fusion Antibodies.


Prof. Laurence Lovat PhD, MBBS, BSc - Clinical advisor

Laurence is a professor of gastroenterology and biophotonics at UCL. He is chief investigator for a large multi-centre project to investigate he detection and treatment of oesophageal cancer, with key connections in the main specialist centres for oesophageal cancer in the UK. He is also special advisor to NICE (National Institute for Health and Care Excellence) who produce evidence based guidance and advice for the NHS and public health and social care services.


Prof. Marco Novelli PhD - Hisopathological advisor

Professor Marco Novelli is a consultant histopathologist at UCLH specialising in colorectal tumorigenesis, Barrett's oesophagus, inflammatory bowel disease and gastrointestinal stromal tumours.



Katy Burdett - Clinical trials co-ordinator

Katy is an experienced clinical research professional with considerable Local / National / International experience within medical devices and pharmaceutical clinical trials. Katy has 9 years experience within the clinical research field and worked for several organizations including charities, manufacturers and CROs (small and large) with their clinical trial projects. Katy has experience conducting feasibility, creating study documentation including protocols, training sites, monitoring and closing out sites.



Prof. Tom Fearn PhD - Statistical advisor

Tom is Head of Statistics at UCL and has over 30 years experience working with clinical research groups producing statistically robust data.